British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.
Havas Health & You introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system,
With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.
ElevateBio, a new company focused on the development of startup cell and gene therapy companies, launched with a $150 million Series A financing round.
Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.
Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.
Philadelphia-based Passage Bio launched with a Series A financing round valued at $115.5 million, led by OrbiMed Advisors.
Axovant Sciences, a clinical-stage company developing innovative gene therapies, today announced the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly formed company.